Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333513 | 0.89 | GSK3B (0.66) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL19862477 | 0.84 | KMT2A (0.47) | KDM4EGAAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5055138 | 0.83 | GSK3B (0.46) | GSK3BPTPN1NPC1MEN1KMT2A | |
| SCHEMBL5801698 | 0.82 | GSK3B (0.61) | GSK3BGAAPTPN1 | |
| SCHEMBL1189829 | 0.82 | GSK3B (0.58) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL23360861 | 0.81 | GSK3B (0.56) | GSK3BKDM4EGAAALDH1A1PTPN1 | |
| SCHEMBL9907157 | 0.81 | GSK3B (0.56) | GSK3BKDM4EGAAPTPN1MEN1 | |
| SCHEMBL5050000 | 0.79 | GSK3B (0.54) | GSK3BKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7821339 | 0.79 | ALDH1A1 (0.56) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL9907151 | 0.78 | GSK3B (0.53) | GSK3BKDM4EGAAALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | GSK3B 1486/4885KDM4E 1877/4885GAA 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.